Ponatinib is a novel potent, orally available small molecule multitargeted kinase inhibitor. Ponatinib inhibits both native and mutant BCR-ABL. Ponatinib is used in the treatment of chronic myeloid leukemia (CML) with BCR-ABL kinase inhibitors. Ponatinib is the active ingredient in the drug product sold under the trade name Iclusig, currently approved in at least one country for use in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia. Synonyms: 3-(2-Imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]benzamide, AP 24534, Iclusig CAS No: 943319-70-8 HCl salt: 114544-31-8 Molecular Formula: C29H27F3N6O Molecular Weight: 532.56 Appearance White to off-white powder Purity: 99% (HPLC) Melting Point: >160C (dec.) Solubility: Soluble in DMSO at 50 mg/mL, soluble in ethanol at 25 mg/mL with warming, very poorly soluble in water, maximum solubility in plain water is estimated to be about 5-10 µM, buffers, serum, or other additives may increase or decrease the aqueous solubility Method for Determining Identity: Proton NMR (DMSO-d6) Spectroscopic and Mass Spectrometric Analysis Storage and Stability: May be stored at RT for short-term only. Long-term storage is recommended at -20C. For maximum recovery of product, centrifuge the original vial prior to removing the cap. Light sensitive. Store under inert atmosphere.
Molekulargewicht:
532.56
Reinheit:
99% (HPLC)
Formulierung:
White to off-white powder
CAS Nummer:
[943319-70-8]
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
